Standardized laboratory monitoring with use of isotretinoin in acne

Timothy J. Hansen, Sara Marian Lucking, Jeffrey J. Miller, Joslyn S. Kirby, Diane M. Thiboutot, Andrea L. Zaenglein

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background Laboratory monitoring for adverse effects to isotretinoin occurs with variability. Standardization of laboratory monitoring practices represents an opportunity to improve quality of care. Objective We sought to develop an evidence-based approach to laboratory monitoring of patients receiving isotretinoin therapy for acne. Methods We reviewed laboratory data from 515 patients with acne undergoing 574 courses of isotretinoin from March 2003 to July 2011. Frequency, timing, and severity of abnormalities were determined. Results Clinically insignificant leukopenia or thrombocytopenia occurred in 1.4% and 0.9% of patients, respectively. Elevated liver transaminases were detected infrequently and not significantly increased compared with baseline detection rates (1.9% vs 1.6% at baseline). Significant elevations occurred with triglyceride (19.3%) and cholesterol (22.8%) levels. The most severe abnormalities were grade 2 (moderate). Mean duration of treatment before abnormalities were detected was 56.3 days for hypertriglyceridemia, 61.9 days for alanine transaminitis, and 50.1 days for hypercholesterolemia. Limitations This was a single-center experience examining variable isotretinoin laboratory monitoring practices. Conclusions In healthy patients with normal baseline lipid panel and liver function test results, repeated studies should be performed after 2 months of isotretinoin therapy. If findings are normal, no further testing may be required. Routine complete blood cell count monitoring is not recommended.

Original languageEnglish (US)
Pages (from-to)323-328
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume75
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Isotretinoin
Acne Vulgaris
Blood Cell Count
Quality of Health Care
Hypertriglyceridemia
Liver Function Tests
Leukopenia
Physiologic Monitoring
Transaminases
Hypercholesterolemia
Thrombocytopenia
Alanine
Triglycerides
Therapeutics
Cholesterol
Lipids
Liver

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{6e1b6b1044734e3c87713b2868b21208,
title = "Standardized laboratory monitoring with use of isotretinoin in acne",
abstract = "Background Laboratory monitoring for adverse effects to isotretinoin occurs with variability. Standardization of laboratory monitoring practices represents an opportunity to improve quality of care. Objective We sought to develop an evidence-based approach to laboratory monitoring of patients receiving isotretinoin therapy for acne. Methods We reviewed laboratory data from 515 patients with acne undergoing 574 courses of isotretinoin from March 2003 to July 2011. Frequency, timing, and severity of abnormalities were determined. Results Clinically insignificant leukopenia or thrombocytopenia occurred in 1.4{\%} and 0.9{\%} of patients, respectively. Elevated liver transaminases were detected infrequently and not significantly increased compared with baseline detection rates (1.9{\%} vs 1.6{\%} at baseline). Significant elevations occurred with triglyceride (19.3{\%}) and cholesterol (22.8{\%}) levels. The most severe abnormalities were grade 2 (moderate). Mean duration of treatment before abnormalities were detected was 56.3 days for hypertriglyceridemia, 61.9 days for alanine transaminitis, and 50.1 days for hypercholesterolemia. Limitations This was a single-center experience examining variable isotretinoin laboratory monitoring practices. Conclusions In healthy patients with normal baseline lipid panel and liver function test results, repeated studies should be performed after 2 months of isotretinoin therapy. If findings are normal, no further testing may be required. Routine complete blood cell count monitoring is not recommended.",
author = "Hansen, {Timothy J.} and Lucking, {Sara Marian} and Miller, {Jeffrey J.} and Kirby, {Joslyn S.} and Thiboutot, {Diane M.} and Zaenglein, {Andrea L.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.jaad.2016.03.019",
language = "English (US)",
volume = "75",
pages = "323--328",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

Standardized laboratory monitoring with use of isotretinoin in acne. / Hansen, Timothy J.; Lucking, Sara Marian; Miller, Jeffrey J.; Kirby, Joslyn S.; Thiboutot, Diane M.; Zaenglein, Andrea L.

In: Journal of the American Academy of Dermatology, Vol. 75, No. 2, 01.08.2016, p. 323-328.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Standardized laboratory monitoring with use of isotretinoin in acne

AU - Hansen, Timothy J.

AU - Lucking, Sara Marian

AU - Miller, Jeffrey J.

AU - Kirby, Joslyn S.

AU - Thiboutot, Diane M.

AU - Zaenglein, Andrea L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background Laboratory monitoring for adverse effects to isotretinoin occurs with variability. Standardization of laboratory monitoring practices represents an opportunity to improve quality of care. Objective We sought to develop an evidence-based approach to laboratory monitoring of patients receiving isotretinoin therapy for acne. Methods We reviewed laboratory data from 515 patients with acne undergoing 574 courses of isotretinoin from March 2003 to July 2011. Frequency, timing, and severity of abnormalities were determined. Results Clinically insignificant leukopenia or thrombocytopenia occurred in 1.4% and 0.9% of patients, respectively. Elevated liver transaminases were detected infrequently and not significantly increased compared with baseline detection rates (1.9% vs 1.6% at baseline). Significant elevations occurred with triglyceride (19.3%) and cholesterol (22.8%) levels. The most severe abnormalities were grade 2 (moderate). Mean duration of treatment before abnormalities were detected was 56.3 days for hypertriglyceridemia, 61.9 days for alanine transaminitis, and 50.1 days for hypercholesterolemia. Limitations This was a single-center experience examining variable isotretinoin laboratory monitoring practices. Conclusions In healthy patients with normal baseline lipid panel and liver function test results, repeated studies should be performed after 2 months of isotretinoin therapy. If findings are normal, no further testing may be required. Routine complete blood cell count monitoring is not recommended.

AB - Background Laboratory monitoring for adverse effects to isotretinoin occurs with variability. Standardization of laboratory monitoring practices represents an opportunity to improve quality of care. Objective We sought to develop an evidence-based approach to laboratory monitoring of patients receiving isotretinoin therapy for acne. Methods We reviewed laboratory data from 515 patients with acne undergoing 574 courses of isotretinoin from March 2003 to July 2011. Frequency, timing, and severity of abnormalities were determined. Results Clinically insignificant leukopenia or thrombocytopenia occurred in 1.4% and 0.9% of patients, respectively. Elevated liver transaminases were detected infrequently and not significantly increased compared with baseline detection rates (1.9% vs 1.6% at baseline). Significant elevations occurred with triglyceride (19.3%) and cholesterol (22.8%) levels. The most severe abnormalities were grade 2 (moderate). Mean duration of treatment before abnormalities were detected was 56.3 days for hypertriglyceridemia, 61.9 days for alanine transaminitis, and 50.1 days for hypercholesterolemia. Limitations This was a single-center experience examining variable isotretinoin laboratory monitoring practices. Conclusions In healthy patients with normal baseline lipid panel and liver function test results, repeated studies should be performed after 2 months of isotretinoin therapy. If findings are normal, no further testing may be required. Routine complete blood cell count monitoring is not recommended.

UR - http://www.scopus.com/inward/record.url?scp=84967166486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967166486&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2016.03.019

DO - 10.1016/j.jaad.2016.03.019

M3 - Article

C2 - 27189824

AN - SCOPUS:84967166486

VL - 75

SP - 323

EP - 328

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -